In high-risk neuroblastoma, MYCN amplification was correlated with SPP enzyme overexpression [15], with NCT-503 treatment inhibiting the growth and survival of MYCN-amplified cell lines, including doxorubicin chemo-resistant BE(2)-C and SMS-KCNR cell lines. This evidence concerns the gene MYCN and neuroblastoma.